← All trials
NCT04210375
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2020
- Primary completion
- Sep 15, 2021
- Completion date
- Mar 15, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 63
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Salubris Biotherapeutics IncLead sponsor
- The Cleveland ClinicOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.